Imfinzi approved in the US as first and only immunotherapy …
3 天之前 · AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.. The approval was granted by the Food and Drug Administration (FDA) after securing Priority Review and Breakthrough Therapy Designation.
Cell therapy in cancer | CAR-T cell therapy | AstraZeneca
2024年4月9日 · Cell therapy plays a pivotal role in our ambition to eliminate cancer as a cause of death. At AstraZeneca, we are advancing multiple strategies aimed at improving the precision and effectiveness of cell therapies for cancer, extending their potential benefit to solid tumours, and overcoming challenges related to scalability and accessibility.
Harnessing the power of cell therapy | AstraZeneca
Adoptive cell therapy (ACT), also known as cellular immunotherapy, uses immune cells to target cancer. Cell therapy is pivotal to our ambition to eliminate cancer as a cause of death and we are exploring the promise of T cell therapies in cancer treatment.
AstraZeneca expands US manufacturing footprint to accelerate …
2024年2月6日 · AstraZeneca is building a cell therapy portfolio that aims to empower and equip the immune system’s T-cells to more effectively fight cancer. The company's research teams are exploring new ways to target and arm CAR-Ts to increase their effectiveness in solid tumours by overcoming the immune-suppressive tumour microenvironment.
Oncology Cell Therapy Unit - AstraZeneca
AstraZeneca is building a cell therapy portfolio that aims to empower and equip T cells, to more effectively fight cancer. We are building on the work already done in blood cancers, where the efficacy potential of chimeric antigen receptor expressing T cells (CAR-T cells) has been demonstrated in some haematological malignancies.
Cell Therapy | AstraZeneca Open Innovation
Explore and identify new compounds from a subset of AstraZeneca small molecules with the potential to act as cell modulators in regenerative medicine. Alternatively, if you are interested in cell modulation with therapeutic antibodies, for some specific targets, we may be able to collaborate and share therapeutic antibodies.
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell …
2023年12月26日 · Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and...
IMFINZI® (durvalumab) approved in the US as first and only ...
3 天之前 · AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.. The approval was granted by the Food and Drug Administration (FDA) after securing Priority Review and Breakthrough Therapy Designation.
FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
3 天之前 · The trial’s subjects were randomly allocated to receive either durvalumab as monotherapy, durvalumab plus tremelimumab, or a placebo. AstraZeneca oncology business unit executive vice-president Dave Fredrickson stated: “This approval for Imfinzi marks a breakthrough for patients with limited-stage small cell lung cancer, allowing them …
AstraZeneca showcases strength of haematology portfolio and …
2024年11月7日 · AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in haematology at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition 7 to 10 December 2024.. A total of 57 abstracts will feature 13 approved and potential new medicines from across AstraZeneca’s portfolio and pipeline in haematology, including ...